Search bioRxivSearch

Biology subjects

Rigau, V.

Publications and source records attributed to Rigau, V..

2 recordsLinked to original sources

Identification of CRYAB+ KCNN3+ SOX9+ astro-like and EGFR+ PDGFRA+ OLIG1+ oligo-like tumoral cells in diffuse low-grade gliomas and implication of Notch1 signalling in their genesis

IDH1-mutated gliomas are slow growing brain tumours, which progress into high-grade gliomas. They present intra-tumoural cell heterogeneity, but no good markers are available to distinguish the different cell subtypes. The molecular mechanisms underlying the formation of this cell diversity is also ill defined. Here we report that the SOX9 and OLIG1 transcription factors, which specifically label astrocytes and oligodendrocytes in the normal brain, reveal the presence of two largely non-overlapping tumoural populations in IDH1-mutated oligodendrogliomas and astrocytomas. Astro-like SOX9+ cells additionally stain for APOE, CRYAB, ID4, KCNN3, while oligo-like OLIG1+ cells stain for ASCL1, EGFR, IDH1, PDGFRA, PTPRZ1, SOX4, and SOX8. GPR17, an oligodendrocytic marker, was expressed by both cells. These two sub-populations appear to have distinct BMP, NOTCH1, and MAPK active pathways as stainings for BMP4, HEY1, HEY2, p-SMAD1/5 and p-ERK were higher in SOX9+ cells. We used primary cultures and a new cell line to explore the influence of NOTCH1 activation and BMP treatment on low-grade glioma cell phenotype. This revealed that NOTCH1 globally reduced oligodendrocytic markers and IDH1 expression while upregulating APOE, CRYAB, HEY1/2 and an electrophysiologically Ca2+-activated apamin-sensitive K+ channel (KCNN3/SK3). This was accompanied by reduction in proliferation. Similar effects of NOTCH1 activation were observed in non-tumoural human oligodendrocytic cells, which additionally induced strong SOX9 expression. BMP treatment reduced OLIG1/2 expression and strongly upregulated CRYAB and NOGGIN, a negative regulator of BMP. The presence of astro-like SOX9+ and oligo-like OLIG1+ cells in diffuse low-grade gliomas raise new questions about their role in the pathology.

cancer biology

The immune landscape of primary central nervous system diffuse large B cell lymphoma

Primary central nervous system diffuse large B-cell lymphoma (PCNSL) is a rare and aggressive entity that resides in an immune-privileged site. The tumor microenvironment (TME) and the disruption of the immune surveillance influence lymphoma pathogenesis and immunotherapy resistance. Despite growing knowledge on heterogeneous therapeutic responses, no comprehensive description of the PCNSL TME is available. We investigated the immune subtypes of PCNSL and their association with molecular signaling and survival. Bulk mRNA-sequencing (n=20) and microarray (n=34) data were exploited to identify three immune subtypes of PCNSL: immune-rich, poor, and intermediate. The immune-rich subtype was associated to better survival and characterized by hyper-activation of STAT3 signaling and inflammatory signaling, e.g., IFN{gamma} and TNF-, resembling the hot subtype described in primary testicular lymphoma and solid cancer. WNT/{beta}-catenin, HIPPO, and NOTCH signaling were hyper-activated in the immune-poor subtype. HLA down-modulation was clearly associated with a low or intermediate immune infiltration and the absence of T-cell activation. Moreover, HLA class I down-regulation was also correlated with worse survival with implications on immune-intermediate PCNSL that frequently feature reduced HLA expression. A ligand-receptor intercellular network revealed high expression of two immune checkpoints, i.e., CTLA-4/CD86 and TIM-3/LAGLS9. Immunohistopathology and digital imaging showed that TIM-3 and galectin-9 proteins were clearly upregulated in PCNSL. Altogether, our study reveals that patient stratification according to immune subtypes, HLA status, and immune checkpoint molecule quantification should be considered prior to immune checkpoint inhibitor therapy. Moreover, TIM-3 protein should be considered an axis for future therapeutic development.

cancer biology